We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Vitamin D Deficiency Linked to Metabolic Changes in Lupus Patients

By LabMedica International staff writers
Posted on 15 Apr 2021
Print article
Image: Lower vitamin D levels are associated with metabolic syndrome and insulin resistance in systemic lupus (Photo courtesy of Nikki Yelton, RD)
Image: Lower vitamin D levels are associated with metabolic syndrome and insulin resistance in systemic lupus (Photo courtesy of Nikki Yelton, RD)
Systemic lupus erythematosus (SLE), is the most common type of lupus. SLE is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. It can affect the joints, skin, brain, lungs, kidneys, and blood vessels.

Metabolic syndrome is a cluster of conditions that occur together, increasing the risk of heart disease, stroke and type 2 diabetes. These conditions include increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels. Metabolic syndrome is increasingly common, and up to one-third of adults in the USA have it.

A large team of immunologists and their international colleagues working with the University of Birmingham (Birmingham, UK) examined vitamin D levels in 1,163 patients with SLE across 33 centers in 11 countries. Clinical, laboratory and therapeutic data were collected. Vitamin D level was defined according to tertiles based on distribution across this cohort, which were set at T1 (10–36 nmol/L), T2 (37–60 nmol/L) and T3 (61–174 nmol/L). Metabolic syndrome was defined according to the 2009 consensus statement from the International Diabetes Federation. Insulin resistance was determined using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) model. Linear and logistic regressions were used to assess the association of variables with vitamin D levels.

The team reported that of the 1,847 patients, 1,163 (63%) had vitamin D measured and 398 (34.2%) subjects were in the lowest 25(OH)D tertile. Metabolic syndrome was present in 286 of 860 (33%) patients whose status could be determined. Patients with lower 25(OH)D were more likely to have metabolic syndrome and higher HOMA-IR. The metabolic syndrome components, hypertension, hypertriglyceridemia and decreased high-density lipoprotein (HDL) were all significantly associated with lower 25(OH)D. Increased average glucocorticoid exposure was associated with higher insulin resistance.

John A. Reynolds, MD, a Consultant Rheumatologist and a senior author of the study. said, “Our results suggest that co-existing physiological abnormalities may contribute to long-term cardiovascular risk early on in systemic lupus erythematosus. We found a link between lower levels of vitamin D and metabolic syndrome and insulin resistance.”

The authors concluded that metabolic syndrome and insulin resistance are associated with lower vitamin D in patients with SLE. Further studies could determine whether vitamin D repletion confers better control of these cardiovascular risk factors and improve long-term outcomes in SLE. The study was published originally published on February 8, 2021 in the journal Rheumatology.

Related Links:
University of Birmingham

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.